Ascendis Pharma

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs.

CEO

Jan Møller Mikkelsen

CEOJan Møller Mikkelsen

Employees

—

Employees—

Headquarters

Hellerup, Capital Region

HeadquartersHellerup, Capital Region

Founded

2006

Founded2006

Employees

—

Employees—

ASND Key Statistics

Market cap

13.15B

Market cap13.15B

Price-Earnings ratio

-51.17

Price-Earnings ratio-51.17

Dividend yield

—

Dividend yield—

Average volume

681.12K

Average volume681.12K

High today

$219.00

High today$219.00

Low today

$213.50

Low today$213.50

Open price

$217.32

Open price$217.32

Volume

302.52K

Volume302.52K

52 Week high

$229.94

52 Week high$229.94

52 Week low

$118.03

52 Week low$118.03

ASND News

TipRanks 1d

Ascendis Pharma Grants New Employee Warrants, Updates Articles of Association

Claim 70% Off TipRanks Premium Ascendis Pharma ( (ASND) ) has issued an announcement. On January 13, 2026, Ascendis Pharma’s board of directors granted 42,030...

TipRanks 4d

Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback

Claim 70% Off TipRanks Premium Ascendis Pharma ( (ASND) ) has shared an announcement. On January 9, 2026, Ascendis Pharma outlined a 2026 business and strateg...

TipRanks 6d

Ascendis Pharma announces $120M share repurchase program

The Board of Directors of Ascendis has authorized a $120M share repurchase program. Claim 70% Off TipRanks Premium Published first on TheFly – the ultimate so...

Analyst ratings

94%

of 17 ratings

Buy

94.1%

Hold

Sell

5.9%

More ASND News

TipRanks 6d

Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Ascendis Pharma. The associated price target was raised to $240.00. Claim 70% Off TipRanks Prem...

TipRanks 7d

Ascendis Pharma price target raised to $322 from $297 at Wells Fargo

Wells Fargo raised the firm’s price target on Ascendis Pharma (ASND) to $322 from $297 and keeps an Overweight rating on the shares. The firm believes shares sh...